financetom
Business
financetom
/
Business
/
CERAWEEK-Williams delays Louisiana natgas pipeline amid competitor dispute
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CERAWEEK-Williams delays Louisiana natgas pipeline amid competitor dispute
Mar 20, 2024 10:44 AM

HOUSTON, March 20 (Reuters) - U.S. energy firm Williams

Companies ( WMB ) has delayed the completion of its Louisiana

Energy Gateway natural gas pipeline project following a dispute

with a rival, Williams CEO Alan Armstrong said on Wednesday at a

conference.

The 1.8-billion cubic feet per day (bcfd) pipeline was

originally set to come online this year but was delayed to the

second half of 2025 following a dispute with Energy Transfer ( ET )

, the company previously said.

The company is still pushing ahead with the project but has

not laid out a new start date, Armstrong said.

Tulsa, Oklahoma-based Williams was able to re-route the line

around the disputed area, he said.

The project, which is under construction in Louisiana and

Texas, will feed gas from the Haynesville shale field to the

Gulf Coast where demand for the fuel is growing to supply

several liquefied natural gas export plants expected to enter

service over the next few years.

Officials at Energy Transfer ( ET ) were not immediately available

for comment.

Other energy firms, including Momentum Midstream and DT

Midstream ( DTM ), have fought with Energy Transfer ( ET ) in court,

accusing Energy Transfer ( ET ) of "blocking" their pipeline projects

by not allowing them to cross Energy Transfer's ( ET ) pipelines in the

area.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SharkNinja Q3 Adjusted Net Income, Sales Increase; Raises 2025 Outlook; Shares Rise
SharkNinja Q3 Adjusted Net Income, Sales Increase; Raises 2025 Outlook; Shares Rise
Nov 6, 2025
07:43 AM EST, 11/06/2025 (MT Newswires) -- SharkNinja ( SN ) reported Q3 adjusted net income Thursday of $1.50 per diluted share, up from $1.21 a year earlier. Analysts polled by FactSet expected $1.32. Net sales for the quarter ended Sept. 30 were $1.63 billion, compared with $1.43 billion a year earlier. Analysts surveyed by FactSet expected $1.60 billion. For...
Madison Square Garden Entertainment Q1 revenue slightly beats estimates
Madison Square Garden Entertainment Q1 revenue slightly beats estimates
Nov 6, 2025
Overview * Madison Square Garden fiscal Q1 revenue grows 14% yr/yr, slightly beating analyst expectations * Adjusted EBIT for fiscal Q1 beats analyst estimates * Company repurchased $25 mln of Class A common stock in fiscal Q1 Outlook * MSG Entertainment expects solid growth in revenue and adjusted operating income for fiscal 2026 Result Drivers * CONCERTS AND EVENTS -...
AAON's Q3 Non-GAAP Net Income Drops, Revenue Rises; Full-Year 2025 Sales Growth Guidance Raised
AAON's Q3 Non-GAAP Net Income Drops, Revenue Rises; Full-Year 2025 Sales Growth Guidance Raised
Nov 6, 2025
07:43 AM EST, 11/06/2025 (MT Newswires) -- AAON ( AAON ) reported Q3 non-GAAP net income Thursday of $0.37 per diluted share, down from $0.63 a year earlier. Analysts polled by FactSet expected $0.32. Revenue for the quarter ended Sept. 30 was $384.2 million, up from $327.3 million a year earlier. Analysts surveyed by FactSet expected $332.9 million. The company...
Cognition Therapeutics Q3 net loss narrows as trials ending lower R&D costs
Cognition Therapeutics Q3 net loss narrows as trials ending lower R&D costs
Nov 6, 2025
Overview * Cognition Therapeutics ( CGTX ) reports Q3 net loss of $4.9 mln, down from $9.9 mln last year * Company completed $30 mln registered direct offering to fund zervimesine development Outlook * Cognition aligns with FDA on zervimesine registration path for Alzheimer's * Cognition's $30 mln offering supports zervimesine's next development stage Result Drivers * R&D EXPENSES -...
Copyright 2023-2026 - www.financetom.com All Rights Reserved